RICHMOND, Calif., Nov. 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in the research and development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification, announced today the appointment of Paul B. Cleveland, executive vice president, corporate development and chief financial officer of Affymax, Inc., to its board of directors, effective November 19, 2008. Mr. Cleveland will also serve as chair of Sangamo's audit committee.
"We are very pleased to welcome Paul to Sangamo's board," stated Edward Lanphier, Sangamo's president and CEO. "His significant experience and success in biotechnology industry finance and business development will aid us in all aspects of our company's operations, including clinical and commercial development of our ZFP Therapeutic(TM) programs."
Mr. Cleveland has served as executive vice president, corporate development and chief financial officer of Affymax, Inc. since January 2006. In such capacity, he has responsibility for all business development, strategic planning, finance, investor relations and legal functions. He negotiated a worldwide collaboration with Takeda that was honored with the "Allicense 2007 Breakthrough Alliance Award" at the Recombinant Capital Allicense conference. Mr. Cleveland also led preparations for and execution of Affymax's initial public offering of common stock which was characterized as "the strongest biotech offering of 2006" by Business Week. Together these transactions added more than $230 million to Affymax's cash balance in one year.
From 2004 to 2006, Mr. Cleveland served as a managing director at
Integrated Finance, Ltd., an investment bank, and from 1996 to 2003 as a
managing director and head of west coast mergers and acquisitions at J.P.
Morgan Chase and Co. (
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved